The TARGET trial: Hit or miss?

European Heart Journal

Volumn 23, Issue 11, 2002, Pages 835-837

  Moliterno, D J ^a   Topol, E J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

CLINICAL RESEARCH; CLINICAL TRIAL; CORONARY STENT; DRUG RESEARCH; EDITORIAL; HEART INFARCTION; HUMAN; INTERVENTIONAL RADIOLOGY; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; CORONARY DISEASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MULTICENTER STUDIES; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; STENTS; TYROSINE;

EID: 0036299260     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.3133     Document Type: Editorial

References (15)

1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
2. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
3. Randomised placebocontrolled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoproteinIIb/IIIa blockade
4. Randomized placebocontrolled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
5. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
6. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial
7. A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: Rationale and design of the TARGET study
8. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
9. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans
10. Ex vivoin vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A
11. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events. Data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial
12. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention
13. A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban
14. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-Assessing Ultegra) multicenter study
15. Comparison of an early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban